We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

By LabMedica International staff writers
Posted on 11 Jul 2025

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. More...

These treatments not only target cancerous areas but also damage healthy tissues, causing side effects that can severely affect patients’ quality of life. Additionally, the treatment often fails to precisely target cancer cells, leading to resistance and recurrence. To overcome these limitations, nanomaterial-based cancer treatments have emerged as a promising solution. However, most current nanomaterials focus on a single function, limiting their therapeutic potential. Now, researchers have developed a new nanomaterial that is capable of simultaneously performing cancer diagnosis, treatment, and immune response induction, paving the way for a next-generation treatment platform.

Scientists at the Korea Research Institute of Standards and Science (KRISS, Daejeon, South Korea) have developed a new triple-layer nanodisk (AuFeAuNDs) that offers multiple therapeutic mechanisms in a single material. The design of the nanodisk, which features iron at the core of a gold structure, provides superior stability compared to traditional spherical materials. The nanodisk is equipped with photoacoustic (PA) imaging capabilities, which allow real-time monitoring of both tumor location and drug delivery. By using a magnet near the tumor site, the nanomaterial's magnetic properties enable precise targeting. In addition, the material performs three types of cancer therapies: photothermal therapy (PTT), chemical dynamic therapy (CDT), and ferroptosis therapy. This multifunctionality is combined with immune response activation, triggering the release of danger-associated molecular patterns (DAMPs) from cancer cells, which helps the immune system recognize and attack recurring cancer cells.

The nanodisk was tested in animal experiments, where PA imaging successfully tracked the accumulation of nanoparticles at the tumor site. The research team confirmed that the optimal treatment time is 6 hours after administering the material. Additionally, the nanodisk induced a significant increase in immune cell count, with up to three times more immune cells identified after treatment. These results highlight the potential of this nanomaterial for improving the effectiveness of cancer treatments and inducing immune responses against cancer recurrence. The findings, published in Chemical Engineering Journal, suggest that this innovative nanomaterial could serve as a platform for next-generation cancer therapy. Future research will focus on optimizing the material's effectiveness in human trials and exploring additional therapeutic applications.

“Unlike conventional nanomaterials, which are composed of a single element and perform only one function, the material developed in this study utilizes the combined properties of gold and iron to perform multiple functions,” said Dr. Lee Eun Sook from KRISS.

Related Links:
KRISS


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Staining System
RAL DIFF-QUIK
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.